No Data
No Data
Institutions Profited After Protara Therapeutics, Inc.'s (NASDAQ:TARA) Market Cap Rose US$60m Last Week but Individual Investors Profited the Most
Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet
TARA Stock Soars on Superior Efficacy of Bladder Cancer Cell Therapy
TD Cowen Maintains Protara Therapeutics(TARA.US) With Buy Rating
We Think Protara Therapeutics (NASDAQ:TARA) Needs To Drive Business Growth Carefully
H.C. Wainwright Maintains Protara Therapeutics(TARA.US) With Buy Rating, Maintains Target Price $23
No Data
Candy077 OP : I'm in this chatroom alone. How am I the only stupid one? There are people in ELAB, and not here. SMH